Abbott has enrolled its first patient in the evaluation of XIENCE PRIME/XIENCE V versus coronary artery bypass surgery for the effectiveness of left main eervascularization (EXCEL) trial.

The global prospective multicentre randomised EXCEL trial will enrol more than 2,600 patients to evaluate the safety and efficacy of the XIENCE PRIME/XIENCE V Everolimus Eluting Coronary Stent Systems, compared to coronary artery bypass grafting (CABG).

The primary endpoint includes composite measure of all-cause mortality, myocardial infarction, or stroke at a median follow-up duration of three years, with all randomised patients having reached a minimum of two years’ follow-up.

The EXCEL trial will also evaluate ‘unprotected’ patients with left main disease who have not received grafts to these arteries to determine whether coronary stenting can be an alternative to bypass surgery in these patients.

Principal investigator of the study Gregg Stone said EXCEL will examine the differences between stenting and surgery in a select patient population.


How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.